Previous 10 | Next 10 |
home / stock / esalf / esalf news
2024-04-16 15:31:20 ET More on Biogen, Eisai, etc. Biogen Inc. (BIIB) Stifel 2024 Virtual CNS Days (Transcript) Eisai: All About Lenvima And Leqembi Biogen Inc. (BIIB) TD Cowen 44th Annual Health Care Conference - (Transcript) GLP-1s benefit Parkinson’...
French Sales Subsidiary Eisai S.A.S. to Divest Rights for Loxapac And Parkinane LP to CNX Therapeutics TOKYO, Apr 3, 2024 - (JCN Newswire) - Eisai Co., Ltd. announced today that its French sales subsidiary Eisai S.A.S. entered into an agreement to transfer the rights in France, the ...
2024-04-01 06:04:15 ET More on Biogen, Eisai Biogen Inc. (BIIB) Stifel 2024 Virtual CNS Days (Transcript) Eisai: All About Lenvima And Leqembi Biogen Inc. (BIIB) TD Cowen 44th Annual Health Care Conference - (Transcript) EU delays decision on Eisai-Biogen Alz...
Eisai Completes Submission of LEQEMBI (lecanemab-irmb) Supplemental Biologics License Application for IV Maintenance Dosing for the Treatment of Early Alzheimer's Disease to the U.S. FDA TOKYO and CAMBRIDGE, Mass., Apr 1, 2024 - (JCN Newswire) - Eisai Co., Ltd. and Biogen Inc. annou...
Eisai to Divest Rights for Merislon and Myonal in Japan to Kaken Pharmaceutical TOKYO, Mar 29, 2024 - (JCN Newswire) - Eisai Co., Ltd. announced today that it has entered into an agreement to divest its rights for vertigo and equilibrium disturbance treatment Merislon (generic name:...
Eisai: Discovery Research on Dual Orexin Receptor Antagonist Lemborexant Honored with PSJ Award for Drug Research and Development 2024 TOKYO, Mar 29, 2024 - (JCN Newswire) - Eisai Co., Ltd. announced today that drug discovery research conducted on lemborexant (brand name: Dayvigo), ...
Eisai's Brain Health Self-Check Tool "NouKNOW" is Certified as "ME-BYO BRAND" by Kanagawa Prefecture TOKYO, Mar 29, 2024 - (JCN Newswire) - Eisai Co., Ltd. announced today that "NouKNOW", Eisai's self-check tool for brain health, was certified as a "ME-BYO BRAND" by Kanagawa prefect...
2024-03-22 08:50:49 ET More on Biogen, Eisai Co., Ltd., etc. Biogen Inc. (BIIB) Stifel 2024 Virtual CNS Days (Transcript) Eisai: All About Lenvima And Leqembi Biogen Inc. (BIIB) TD Cowen 44th Annual Health Care Conference - (Transcript) Biogen chief medical o...
Lifenet and Eisai Co-Develop Dementia Insurance "be" TOKYO, Mar 21, 2024 - (JCN Newswire) - LIFENET INSURANCE COMPANY and Eisai Co., Ltd. announced today that they have co-developed Dementia Insurance "be", a dementia insurance that supports early detection and treatment of dementia...
Eisai Selected as a Nadeshiko Brand 2024 as a Listed Company Excelling in Promotion of Women in the Workplace TOKYO, Mar 21, 2024 - (JCN Newswire) - Eisai Co., Ltd. announced today that it has been selected for the first time by the Ministry of Economy, Trade and Industry (METI) and...
News, Short Squeeze, Breakout and More Instantly...
Eisai Co Ltd Company Name:
ESALF Stock Symbol:
OTCMKTS Market:
"LEQEMBI" Lecanemab) Approved for the Treatment of Alzheimer's Disease in Israel TOKYO and CAMBRIDGE, Mass., July 12, 2024 - (JCN Newswire) - Eisai Co., Ltd. and Biogen Inc. announced today that humanized anti-soluble aggregated amyloid-beta (Aβ) monoclonal antibody "LEQEMB...
"LEQEMBI" (Lecanemab) Approved for the Treatment of Alzheimer's Disease in Hong Kong TOKYO and CAMBRIDGE, Mass., July 11, 2024 - (JCN Newswire) - Eisai Co., Ltd. and Biogen Inc. announced today that the Department of Health in HongKong has approved humanized anti-soluble aggregated ...
Eisai Announces Move to Solo Development and Commercialization of Farletuzumab Ecteribulin (FZEC) Antibody Drug Conjugate (ADC) TOKYO, July 2, 2024 - (JCN Newswire) - Eisai Co., Ltd. announced today that it has agreed to end its global strategic collaboration with Bristol Myers Squi...